Journal of the National Cancer Institute 2005-09-07
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
ABSTRACT
BACKGROUND
Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether extended adjuvant therapy with the aromatase inhibitor letrozole after tamoxifen reduces the risk of such late recurrences, was stopped early after an interim analysis showed that letrozole improved disease-free survival. This report presents updated findings from the trial.
METHODS
Postmenopausal women completing 5 years of tamoxifen treatment were randomly assigned to a planned 5 years of letrozole (n = 2593) or placebo (n = 2594). The primary endpoint was disease-free survival (DFS); secondary endpoints included distant disease-free survival, overall survival, incidence of contralateral tumors, and toxic effects. Survival was examined using Kaplan-Meier analysis and log-rank tests. Planned subgroup analyses included those by axillary lymph node status. All statistical tests were two-sided.
RESULTS
After a median follow-up of 30 months (range = 1.5-61.4 months), women in the letrozole arm had statistically significantly better DFS and distant DFS than women in the placebo arm (DFS: hazard ratio [HR] for recurrence or contralateral breast cancer = 0.58, 95% confidence interval [CI] = 0.45 to 0.76; P < .001; distant DFS: HR = 0.60, 95% CI = 0.43 to 0.84; P = .002). Overall survival was the same in both arms (HR for death from any cause = 0.82, 95% CI = 0.57 to 1.19; P = .3). However, among lymph node-positive patients, overall survival was statistically significantly improved with letrozole (HR = 0.61, 95% CI = 0.38 to 0.98; P = .04). The incidence of contralateral breast cancer was lower in women receiving letrozole, but the difference was not statistically significant. Women receiving letrozole experienced more hormonally related side effects than those receiving placebo, but the incidences of bone fractures and cardiovascular events were the same.
CONCLUSION
Letrozole after tamoxifen is well-tolerated and improves both disease-free and distant disease-free survival but not overall survival, except in node-positive patients.
Related Questions
How would you approach a patient who is intolerant of AI and develops thrombosis while on SERM?
New answer by Medical Oncologist at Texas Oncology (August 12, 2021)
Keep in mind that there was RCT of aromatase inhibitor use versus non-use that showed an increased risk of VTE, although not as high as tamoxifen.
New answer by Medical Oncologist at Warren Alpert Medical School of Brown University (December 10, 2019)
This can be a complicated decision for which you need to take into consideration the patient's estimated risk of late recurrence, her understanding of that risk, how well (or ...
If the cancer was also HER2+, would that influence your decision?
New answer by Medical Oncologist at Sarah Cannon Research Institute (June 9, 2020)
The survival benefit for OS is among LN + patients, not LN-. So, it would depend on clinical risk and nodal status for me. If she is node negative, odds are she will not get s...
Would you consider OFS this far out from diagnosis and treatment in a young patient with high grade IDC was treated during pregnancy with neoadjuvant ...
New answer by Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida (December 12, 2023)
I would if you are considering extending her endocrine therapy based on clinical risk or other info like BCI testing. If she took tamoxifen alone then I would discuss OFS+AI b...